FDA Inspection 1301040 — Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. — FEI 3026012834

The FDA completed an inspection of Regeneron Pharmaceuticals, Inc. on Mar 27, 2026 in Armonk, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Mar 27, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Armonk, NY (United States)

Additional details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.